Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?

Megna, Matteo; Potestio, Luca; Fabbrocini, Gabriella; Cinelli, Eleonora

Megna, Matteo; Potestio, Luca; Fabbrocini, Gabriella; Cinelli, Eleonora.

Afiliación

Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.
Potestio L; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.
Fabbrocini G; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.
Cinelli E; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.

Dermatol Ther ; 34(5): e15030, 2021 09.

Article en En | MEDLINE | ID: mdl-34137492

Asunto(s)

Anticuerpos Monoclonales Humanizados; Psoriasis; Humanos; Psoriasis/diagnóstico; Psoriasis/tratamiento farmacológico; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Humanizados Tipo de estudio: Diagnostic_studies Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google